Byotrol : Annual Report and Accounts

Byotrol Plc

Annual Report

and

Financial Statements

for the year ended 31 March 2023

Registered number: 05352525

COMPANY INFORMATION

Directors	Nominated Adviser and Stockbroker
Dr Trevor Francis (Non-executive Chairman)	finnCap Limited
Sean Gogarty (Non-executive Director)	1 Bartholomew Close
David Traynor (Executive Director)	London
Christopher Sedwell (Chief Financial Officer)	EC1A 7BL
Vivan Pinto (Chief Executive Officer)
Auditor	Solicitors
Crowe U.K. LLP	Field Fisher Waterhouse LLP
3rd floor, The Lexicon	35 Vine Street
Mount Street	London
Manchester	EC3N 2AA
M2 5NT
Bankers
Barclays Bank plc	Share Capital
3 Hardman Street
Manchester	The ordinary share capital of Byotrol Plc is admitted to trading on
M3 3HF	AIM, a market operated by London Stock Exchange Group plc. The
	shares are quoted under the trading ticker BYOT
HSBC
69 High Street	The ISIN number is GB00B0999995 and the SEDOL number is
Sevenoaks	B099999
Kent
TN13 1LB
Registrars	Registered Office Address
	Riverside Works
Link Group	Collyhurst Road
Central Square	Manchester
29 Wellington Street	M40 7RU
Leeds
LS1 4DL	Trading Address
	Building 303 (Ashton)
Shareholder enquiries:	Thornton Science Park
Tel. [phone]* (from UK); [phone] (from	Pool Lane
overseas)	Ince
* lines are open from 8.30am to 5.30pm Monday to Friday	Chester
	CH2 4NU
	Website
	https://byotrolplc.com/

Board of Directors

CONTENTS

Byotrol plc

• About Byotrol
• Board of Directors
• Chairman's statement
• CEO's report

Strategic Report

• Key Performance Indicators
• Principal risks and uncertainties
• Financial review
• s.172 statement

Corporate governance review

Report of the Directors and Financial Statements

• Directors' report
• Independent auditor's report
• Group statement of comprehensive income
• Group statement of financial position
• Group statement of cash flow
• Group statement of changes in equity
• Notes to the Group financial statements
• Company statement of financial position
• Company statement of changes in equity
• Notes to the Company financial statements

About Byotrol

Byotrol strives to revolutionise biosecurity and infection control, by developing new technologies and protocols designed to protect people and animals from disease. Byotrol's unique products are grounded in excellent science; developed by a team of hygiene experts and supported by robust data that customers trust. We specialise in high performance, sustainable and regulatory-approved antimicrobial technologies and products, especially those which challenge traditional sanitisation and cleaning methods.

We firmly believe in the responsible use of biocides in our society and that Byotrol products should perform as well in real life environments as they do in a laboratory. Our commitment to the robust testing of our products during development enables our customers and end-users to trust that Byotrol products will always perform as they should.

Byotrol understands that every business and consumer needs access to good hygiene practices and effective antimicrobial products, and we are committed to developing the most effective technology, at the best possible price to make our products accessible to everyone.

Our technologies are utilised across professional and consumer markets, in products for both surfaces and skin, in environments where good hygiene is of the greatest importance. Byotrol's laboratories are based at Thornton Science Park, a University of Chester campus in the North-West of England, where the Group also hosts its commercial operations.

Byotrol's territories of sale have grown significantly in recent years and our products are now sold and used throughout Europe, North America, South Africa and Asia. Byotrol is active in the following market sectors:

• Professional
• • Human Health
  • Animal Health
  • Facilities Management
• Consumer
• • Household
  • Skin Care
  • Pet Care

At Byotrol, we have established the following core values which are the foundation of the ethical and cultural expectations of the Company, and sit under the acronym CARE:

• Collaborative - We communicate proactively and promote a culture of transparency and accountability.
• Act with Integrity - Doing the 'right thing' is in our DNA, we lead with integrity, respect, and compassion.
• Responsible - We strive to make a positive impact on society and our environment.
• Entrepreneurial Spirit - We encourage the development of innovative solutions and support creative thinking.

4	Byotrol Plc

Byotrol's corporate history

1990's Byotrol's first antimicrobial technology was invented and patented

2005 The Company floated on the London AIM market

2007 Byotrol Consumer Products set up in joint venture with Byotrol plc and WhatIf Ventures

2010 First consumer hand sanitiser launched in Boots

2011 Consumer household surface care range launched in Tesco

2013 Byotrol plc acquired remaining share of Byotrol Consumer Products from WhatIf Ventures

2014 Actizone patent granted in the UK

2016 PAS 2424 long-lasting antimicrobial test method developed in conjunction with the BSI

2017 Byotrol launches new Invirtu alcohol free hand sanitiser: the US Environmental Protection Agency grant approval of Byotrol's proprietary 24-hourgerm-kill surface sanitiser

2018 Byotrol acquires Medimark Scientific Limited, a leading provider of biocide-based infection control products for the animal and human healthcare markets

2019 Byotrol sells patents and underlying IP to Solvay SA, whilst retaining rights to sell Actizone in finished product form; completes licences with two key suppliers into UK NHS - with SC Johnson Professional on alcohol free hand sanitisers; and with Tristel on (non-sporicidal)anti-microbial surface care chemistries

2020 Byotrol accelerates earnout payments relating to Medimark Scientific, allowing final integration of the two companies

2021 Byotrol achieves significant profitability; licences technology to transfer US operations to third party

2022 Byotrol centralises its commercial operations into Thornton Science Park, alongside the existing laboratory facilities

2023 Following the launch of the Cruise formulation within the Anigene brand in late 2022, Byotrol focuses on rolling out it's BPR-approvable Cruise technology across a wide range of its product portfolio, providing a sustainable platform for growth in the tightening regulatory environments of both UK and Export markets. In the US, the Environmental Protection Agency "EPA" formally approved long-lasting virucidal claims for Byotrol24, which the Directors believe is the first product to receive such an EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses.

5	Byotrol Plc